U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Platinum-Sensitive Fallopian Tube Carcinoma

MedGen UID:
1690334
•Concept ID:
C5205620
•
Neoplastic Process
Synonym: Platinum-Sensitive Fallopian Tube Cancer

Definition

Fallopian tube carcinoma that has a documented response to platinum-based chemotherapy. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVPlatinum-Sensitive Fallopian Tube Carcinoma

Professional guidelines

PubMed

New strategies in ovarian cancer treatment.
Lee JM, Minasian L, Kohn EC
Cancer 2019 Dec 15;125 Suppl 24(Suppl 24):4623-4629. doi: 10.1002/cncr.32544. PMID: 31967682Free PMC Article
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.
Kurnit KC, Coleman RL, Westin SN
Curr Treat Options Oncol 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7. PMID: 30535808Free PMC Article
Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer.
Webber K, Friedlander M
Best Pract Res Clin Obstet Gynaecol 2017 May;41:126-138. Epub 2016 Nov 23 doi: 10.1016/j.bpobgyn.2016.11.004. PMID: 28027849

Recent clinical studies

Etiology

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2021 May;22(5):620-631. Epub 2021 Mar 18 doi: 10.1016/S1470-2045(21)00073-5. PMID: 33743851
Efficacy and Safety of Pembrolizumab in Combination With Bevacizumab and Oral Metronomic Cyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial.
Zsiros E, Lynam S, Attwood KM, Wang C, Chilakapati S, Gomez EC, Liu S, Akers S, Lele S, Frederick PJ, Odunsi K
JAMA Oncol 2021 Jan 1;7(1):78-85. doi: 10.1001/jamaoncol.2020.5945. PMID: 33211063Free PMC Article
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS
N Engl J Med 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626. PMID: 31722153Free PMC Article
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25 doi: 10.1016/S1470-2045(17)30469-2. PMID: 28754483
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article

Diagnosis

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2021 May;22(5):620-631. Epub 2021 Mar 18 doi: 10.1016/S1470-2045(21)00073-5. PMID: 33743851
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS
N Engl J Med 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626. PMID: 31722153Free PMC Article
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25 doi: 10.1016/S1470-2045(17)30469-2. PMID: 28754483
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR
J Clin Oncol 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23 doi: 10.1200/JCO.2012.42.0505. PMID: 22529265Free PMC Article

Therapy

Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A, Floquet A, Ledermann JA, Asher R, Penson RT, Oza AM, Korach J, Huzarski T, Pignata S, Friedlander M, Baldoni A, Park-Simon TW, Tamura K, Sonke GS, Lisyanskaya A, Kim JH, Filho EA, Milenkova T, Lowe ES, Rowe P, Vergote I, Pujade-Lauraine E; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2021 May;22(5):620-631. Epub 2021 Mar 18 doi: 10.1016/S1470-2045(21)00073-5. PMID: 33743851
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
Coleman RL, Spirtos NM, Enserro D, Herzog TJ, Sabbatini P, Armstrong DK, Kim JW, Park SY, Kim BG, Nam JH, Fujiwara K, Walker JL, Casey AC, Alvarez Secord A, Rubin S, Chan JK, DiSilvestro P, Davidson SA, Cohn DE, Tewari KS, Basen-Engquist K, Huang HQ, Brady MF, Mannel RS
N Engl J Med 2019 Nov 14;381(20):1929-1939. doi: 10.1056/NEJMoa1902626. PMID: 31722153Free PMC Article
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, Korach J, Huzarski T, Poveda A, Pignata S, Friedlander M, Colombo N, Harter P, Fujiwara K, Ray-Coquard I, Banerjee S, Liu J, Lowe ES, Bloomfield R, Pautier P; SOLO2/ENGOT-Ov21 investigators
Lancet Oncol 2017 Sep;18(9):1274-1284. Epub 2017 Jul 25 doi: 10.1016/S1470-2045(17)30469-2. PMID: 28754483
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain A, Sovak MA, Yi J, Nycum LR
J Clin Oncol 2012 Jun 10;30(17):2039-45. Epub 2012 Apr 23 doi: 10.1200/JCO.2012.42.0505. PMID: 22529265Free PMC Article

Prognosis

Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
Ha HI, Park EY, Eoh KJ, Lee YJ, Seo SS, Kang S, Park SY, Lim MC
Gynecol Oncol 2022 Feb;164(2):415-420. Epub 2021 Dec 17 doi: 10.1016/j.ygyno.2021.12.013. PMID: 34924242
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators
Lancet 2017 Oct 28;390(10106):1949-1961. Epub 2017 Sep 12 doi: 10.1016/S0140-6736(17)32440-6. PMID: 28916367Free PMC Article
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
Coleman RL, Brady MF, Herzog TJ, Sabbatini P, Armstrong DK, Walker JL, Kim BG, Fujiwara K, Tewari KS, O'Malley DM, Davidson SA, Rubin SC, DiSilvestro P, Basen-Engquist K, Huang H, Chan JK, Spirtos NM, Ashfaq R, Mannel RS
Lancet Oncol 2017 Jun;18(6):779-791. Epub 2017 Apr 21 doi: 10.1016/S1470-2045(17)30279-6. PMID: 28438473Free PMC Article
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA
Lancet Oncol 2017 Jan;18(1):75-87. Epub 2016 Nov 29 doi: 10.1016/S1470-2045(16)30559-9. PMID: 27908594
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Aravantinos G, Pectasides D
J Ovarian Res 2014;7:57. Epub 2014 May 19 doi: 10.1186/1757-2215-7-57. PMID: 24864163Free PMC Article

Clinical prediction guides

Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study.
Abe M, Shoji T, Chiba Y, Takatori E, Kaido Y, Nagasawa T, Kagabu M, Takahashi F, Aida T, Baba T
Anticancer Res 2023 Mar;43(3):1265-1272. doi: 10.21873/anticanres.16273. PMID: 36854492
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, Wahner Hendrickson AE, Azodi M, DiSilvestro P, Oza AM, Cristea M, Berek JS, Chan JK, Rimel BJ, Matei DE, Li Y, Sun K, Luptakova K, Matulonis UA, Monk BJ
Lancet Oncol 2019 May;20(5):636-648. Epub 2019 Apr 1 doi: 10.1016/S1470-2045(19)30029-4. PMID: 30948273
Olaparib Tablet: A Review in Ovarian Cancer Maintenance Therapy.
Heo YA, Dhillon S
Target Oncol 2018 Dec;13(6):801-808. doi: 10.1007/s11523-018-0606-x. PMID: 30456461
Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA
Lancet Oncol 2017 Jan;18(1):75-87. Epub 2016 Nov 29 doi: 10.1016/S1470-2045(16)30559-9. PMID: 27908594
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Aravantinos G, Pectasides D
J Ovarian Res 2014;7:57. Epub 2014 May 19 doi: 10.1186/1757-2215-7-57. PMID: 24864163Free PMC Article

Recent systematic reviews

Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer.
Newhouse R, Nelissen E, El-Shakankery KH, Rogozińska E, Bain E, Veiga S, Morrison J
Cochrane Database Syst Rev 2023 Jul 5;7(7):CD006910. doi: 10.1002/14651858.CD006910.pub3. PMID: 37407274Free PMC Article
Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review.
Aravantinos G, Pectasides D
J Ovarian Res 2014;7:57. Epub 2014 May 19 doi: 10.1186/1757-2215-7-57. PMID: 24864163Free PMC Article

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...